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 The GPVI collagen receptor mediates
platelet activation to collagen exposed
after rupture or injury of atherosclerotic
plaques. Revacept, a GPVI-Fc fusion
protein binding to plaque collagen and
concealing binding sites for platelet GPVI,
acts as a lesion-focused antiplatelet drug.
To optimize its speciﬁc inhibition of
plaque-induced platelet activation, we
cross-linked the Fc tails of GPVI-Fc with
anti-human-Fc IgG or Fab2 antibodies.
 Cross-linking yielded oligomeric GPVI-Fc
complexes, which inhibited atheroscle-
rotic plaque- induced platelet aggrega-
tion in static and ﬂow assays as efﬁciently
as antibodies blocking GPVI receptors on
platelets. Under arterial ﬂow, GPVI-Fc
cross-linking with anti-Fc-Fab2 was su-
perior to cross-linking with anti-Fc IgG.
 Advanced optical imaging revealed a
rapid and stable sheath-like coverage of
collagen ﬁbers by cross-linked GPVI-Fc
complexes preventing platelet attach-
ment to collagen.
 Cross-linked GPVI-Fc did not increase
bleeding time in vitro.
 Transformation of GPVI into multivalent
GPVI complexes may provide a new
superior strategy to suppress
atherothrombosis without increasing
systemic bleeding risk.
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authors incubated GPVI-Fc with anti-human Fc antibodies to cross-link the Fc tails of GPVI-Fc. Cross-linking
potentiated the inhibition of human plaque- and collagen-induced platelet aggregation by GPVI-Fc under static
and ﬂow conditions without increasing bleeding time in vitro. Cross-linking with anti-human-Fc Fab2 was even
superior to anti-human-Fc immunoglobulin G (IgG). Advanced optical imaging revealed a continuous sheath-like
coverage of collagen ﬁbers by cross-linked GPVI-Fc complexes. Cross-linking of GPVI into oligomeric complexes
provides a new,highly effective, andprobably safe antithrombotic treatment as it suppressesplateletGPVI-plaque
interaction selectively at the site of acute atherothrombosis. (J Am Coll Cardiol Basic Trans Science 2016;1:131–42)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).E rosion or rupture of atherosclerotic plaquesexposes material to circulating blood that trig-gers thrombosis and can precipitate myocar-
dial infarction and stroke, which are leading causes
of death worldwide (1,2). Decisive thrombogenic pla-
que components include collagen type I and III ﬁbers,
which trigger platelet deposition under static and
ﬂow conditions by activating the platelet glycopro-
tein VI (GPVI) receptor (3–6). The alternative collagen
receptor, a2b1-integrin, is not involved in plaque-
induced platelet aggregation (4,6). Therefore, target-
ing GPVI might preferentially inhibit atherosclerotic
plaque–induced thrombosis and should not affect
other cells because GPVI expression is restricted to
platelets and megakaryocytes (7). Only the dimeric
form of GPVI binds to collagen with high afﬁnity
(8,9), recognizing mostly tandem glycine-proline-
hydroxyproline motifs but also other peptide se-
quences of collagen ﬁbers (10,11).
The GPVI–collagen interaction can be inhibited
either by occupation of GPVI-binding sites on
collagen using a dimeric glycoprotein VI–fragment
crystallizable (GPVI-Fc) fusion protein (Revacept;
advanceCOR, Munich, Germany) or by antibodies
directed against platelet GPVI (7,12–15). Anti-GPVI
antibodies might increase bleeding, as observed in
some patients with anti-GPVI autoantibodies (14,15),stitute for the Prevention of Cardiovascular Diseases, Unive
ar Research Institute Maastricht, Maastricht University, Maastr
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ceived January 26, 2016; accepted March 8, 2016.whereas GPVI-Fc might be safer because it did not
increase bleeding time in a Phase I study (13). Anti-
GPVI antibodies are systemic and potent inhibitors
of plaque- and collagen-induced platelet aggregation
under static and ﬂow conditions, whereas GPVI-Fc
acts locally at the site of plaque rupture and is
in vitro most effective under high shear ﬂow (16).
However, GPVI-Fc inhibition of plaque-induced
platelet aggregation in static assays and at low arte-
rial shear ﬂow is inferior to anti-GPVI antibodies (16).
GPVI-Fc, even at very high concentrations, appar-
ently cannot saturate all binding sites on plaque
collagen. The goal of the present study, therefore,
was to improve the efﬁcacy of GPVI-Fc binding to
exposed plaque collagen to combine its lesion selec-
tivity with the full potential of GPVI antagonism as
demonstrated by the anti-GPVI antibodies.
METHODS
Carotid atherosclerotic plaque tissue donated by pa-
tients undergoing endarterectomy for high-grade ca-
rotid stenosis was processed, homogenized, and
preserved as described elsewhere (5,16,17). Plaque
homogenates from 5 patients were pooled, and ali-
quots were used to stimulate platelet aggregation
under static conditions or were coated onto glass
coverslips for ﬂow studies (16,18,19). In addition torsity of Munich (LMU Munich), Munich, Germany;
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133plaque, which contains mainly type I and III collagens
(4,6), blood was exposed to Horm collagen ﬁbers also
consisting of type I and III collagens (16).
Nanoscopic imaging of GPVI-Fc binding and
platelet adhesion to collagen under ﬂow was per-
formed by structured illumination microscopy (SIM)
(20) and stimulated emission depletion (STED) mi-
croscopy. Additional details are presented in the
Supplemental Appendix.
STATISTICAL ANALYSIS. The means of 2 parallel
experimental conditions were compared by using the
Student t test or, if normality was not assured, by
using the Mann-Whitney U test as indicated in the
ﬁgure legends. More than 2 concurrent experimental
conditions using the same samples were tested by
using repeated measures analysis of variance. If
normality was not assured by repeated measures,
analysis of variance on ranks was used followed by
pair-wise comparisons with p values based on a
Tukey adjustment for multiple testing.
RESULTS
GPVI-Fc, even at very high concentrations, apparently
cannot saturate all binding sites on plaque collagen
and incompletely inhibits platelet aggregation (16).
To gain further insights into the underlying mecha-
nism, we studied the kinetics and spacial distribution
at low shear ﬂow (600/s) of how ﬂuorescent GPVI-Fc
added to blood accretes on collagen ﬁbers and how
this affects platelet adhesion, which precedes platelet
aggregation. We noted that GPVI-Fc binding to
collagen was very fast (Video 1), and dense GPVI-Fc
dots could repel arrested platelets from stably
adhering to collagen (Figure 1A). However, the plate-
lets settled preferentially on segments of collagen
ﬁbers carrying little GPVI-Fc (Figures 1A and 1B), and
they were even able to displace neighboring collagen-
bound GPVI-Fc to ﬁrmly attach to these collagen
segments. Use of SIM conﬁrmed that platelets stably
adhered to the segments of collagen ﬁbers, which
carried little GPVI-Fc (Figure 1C, Video 2).
We therefore aimed to modify GPVI-Fc in such a
way that it would assure a more continuous binding
to collagen and resist displacement by platelets. We
hypothesized that anti–Fc-mediated cross-linking of
the Fc tails would more closely align GPVI-Fc mole-
cules to their corresponding binding motifs on
collagen. We thus pre-incubated anti–human-Fc
immunoglobulin G (IgG) and Fab2 antibodies at
equimolar concentrations with GPVI-Fc to allow the
formation of cross-linked (XL) complexes (GPVI-
Fc*IgG-XL and GPVI-Fc*Fab2-XL). Pre-incubation
of blood with GPVI-Fc*IgG-XL or GPVI-Fc*Fab2-XLinhibited static platelet aggregation stimulated by
plaque or collagen more effectively than GPVI-Fc
alone (Figure 2A). For plaque-stimulated samples,
inhibition by GPVI-Fc*IgG-XL was 72  12% compared
with 35  13% by GPVI-Fc, and inhibition by GPVI-
Fc*Fab2-XL was 84  10% compared with 40  13% by
GPVI-Fc. For collagen-stimulated samples, inhibition
by GPVI-Fc*IgG-XL was 60  17% compared with 20 
17% by GPVI-Fc, and inhibition by GPVI-Fc*Fab2-XL
was 67  21% compared with 18  9% by GPVI-Fc.
Bare Fc protein cross-linked with anti–human-Fc IgG
or anti–human-Fc Fab2 (Fc*IgG-XL; Fc*Fab2-XL) or
IgG or Fab2 alone did not inhibit platelet aggregation.
Concentration–response curves of GPVI-Fc*Fab2-XL
showed superior inhibition by GPVI-Fc*Fab2-XL at
all concentrations starting with 33 nM for plaque- and
collagen-stimulated samples (Figure 2B). These con-
centrations are well below the maximal plasma GPVI-
Fc concentrations (50 mg/ml ¼ 333 nM) that were
reached after intravenous application in a previous
Phase I clinical study (13).
We then explored the effects of GPVI-Fc antibody
cross-linking on plaque-induced platelet aggregation
under ﬂow. Coronary thrombosis mostly arises from
rupture of thin-capped (<65 mm) ﬁbroatheroma,
exposing the plaque lipid core containing collagenous
structures to circulating blood (6,21,22). This action
creates a new thrombogenic and rough luminal sur-
face that will inﬂuence platelet adhesion and aggre-
gation dynamics probably similar to our plaque
model. In our model, plaque fragments of different
sizes and consisting of lipids and collagenous struc-
tures are exposed to arterially ﬂowing blood (4,16).
The subtle (<8 mm) roughness of the plaque surface in
our model created local differences in dynamics and
extent of plaque-induced platelet aggregate forma-
tion at ﬂow. For comparison, ﬂow experiments using
collagen-coated surfaces were also performed.
As depicted in the micrographs and diagrams in
Figures 3A and 3B, GPVI-Fc*IgG-XL inhibited plaque-
stimulated aggregate formation at any time after the
start of ﬂow much more efﬁciently than GPVI-Fc.
With GPVI-Fc*Fab2-XL, the inhibition was even
more pronounced, and GPVI-Fc*Fab2-XL virtually
abolished platelet accretion on plaque material.
Interestingly, inhibition of plaque-induced platelet
aggregate formation by GPVI-Fc*IgG-XL and GPVI-
Fc*Fab2-XL at the end of ﬂow was more pronounced
than after collagen stimulation.
We then compared the binding kinetics of labeled
GPVI-Fc and cross-linked GPVI-Fc to collagen to
explore whether a faster binding of cross-linked
GPVI-Fc might explain its better inhibitory effect.
Perfusion of collagen-coated coverslips with blood
FIGURE 1 Dynamics of GPVI-Fc Binding and Platelet Adhesion to Collagen Under Flow
Glycoprotein VI–fragment crystallizable (GPVI-Fc) (50 mg/ml ﬁnal concentration; 333 nM) labeled with phycoerythrin (PE)-conjugated anti–human-Fc antibody (red) was
added to blood containing abciximab (to inhibit platelet aggregation and allow only platelet adhesion) before perfusion over collagen (550/s). Differential interference
contrast (DIC) and ﬂuorescence images were taken by video microscopy (1 frame/2 s) using a 100 NA1.4 oil objective. Images are representative for 6 individual
experiments. Upper rows: overlay of DIC (collagen/platelets) and ﬂuorescence (PE-labeled GPVI-Fc) images. Bottom rows: ﬂuorescence images of PE-labeled GPVI-Fc.
See also Video 1. (A) A single platelet (thick arrow) rolls over PE-labeled GPVI-Fc (thin arrows in row below) bound to collagen. Two platelets (asterisks) adhere to
segments of collagen ﬁbers that contain less ﬂuorescent GPVI-Fc. (B) A single platelet (arrow, top row) attaching downstream of the ﬁber and moving back against the
blood ﬂow displaces GPVI-Fc-PE from collagen (arrows in bottom row). (C) Structured illumination microscopy imaging. Platelets adhere to collagen segments carrying
little GPVI-Fc. Collagen coated onto glass coverslips was stained with anti–collagen type I and type III antibody (Ab) and AlexaFluor405-conjugated secondary Ab (blue).
PE-labeled GPVI-Fc (50 mg/ml) was added to blood containing Arg-Gly-Asp-Ser (to inhibit platelet aggregation and allow only platelet adhesion) before the start of
perfusion (shear rate 550/s). After 4 min of ﬂow, platelets were ﬁxed and stained with anti-CD41 Ab and DyLight 488-conjugated secondary Ab (green). The ﬂuo-
rescence micrograph shows a maximum intensity projection of 0.15 mm z sections (total z 2.5 mm) of a structured illumination microscopy image (ELYRA PS.1; Carl Zeiss
MicroImaging GmbH, Jena, Germany). i and ii, Identical pictures. i, Binding of GPVI-Fc (red) onto collagen ﬁbers (blue). Green channel (platelets) was omitted. ii, Picture
as in i but with platelets (green). Image is representative of 5 others from different experiments. Video 2 presents a 3-dimensional representation.
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FIGURE 2 Cross-Linking of GPVI-Fc With Anti–Human-Fc IgG and Anti–Human-Fc Fab2 Increases Inhibition of Static Platelet Aggregation
Induced by Collagen or Plaque Compared With GPVI-Fc
(A) Bar diagrams show the effects of glycoprotein VI–fragment crystallizable (GPVI-Fc) (20 mg/ml; 133 nM), GPVI-Fc, and Fc cross-linked (XL)
with anti–human-Fc immunoglobulin G (IgG) (GPVI-Fc*IgG-XL, Fc*IgG-XL; 133 nM) (left panels) or with anti–human-Fc Fab2 (GPVI-Fc*Fab2-
XL, Fc*Fab2-XL; 133 nM) (right panels) on plaque- or collagen-induced platelet aggregation. Further controls were anti–human-Fc IgG (133 nM)
(left panels) and anti–human-Fc Fab2 (133 nM) (right panels). Cumulative platelet aggregation (AU*min) was measured by using multiple
electrode aggregometry. Mean  SD; n ¼ 4. Repeated measures analysis of variance (overall p < 0.001) with secondary pair-wise comparisons
(as indicated by bars) by Tukey correction. (B) Concentration dependency of the effects of GPVI-Fc*Fab2-XL on plaque- and collagen-induced
platelet aggregation compared with GPVI-Fc. Mean  SD; n ¼ 4 to 6. Comparisons were made by using the Student t test or, if inappropriate,
by using the Mann-Whitney U test (at 333 nM with plaque and at 33 nM with collagen). *p < 0.05; **p < 0.01; ***p < 0.001.
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135containing phycoerythrin (PE)-labeled cross-linked
GPVI-Fc (GPVI-Fc*Fab2-XL) or PE-labeled GPVI-Fc
(GPVI-Fc*Fab2) revealed that GPVI-Fc*Fab2-XL
bound only slightly faster than GPVI-Fc*Fab2
(Figure 3C, Videos 3 and 4). Similar observations
were made with GPVI-Fc*IgG and GPVI-Fc*IgG-XL
(data not shown). As demonstrated by the ﬂuores-
cence intensity surface plots, the ﬁnal GPVI-Fc*Fab2-
XL binding to collagen was much higher than that of
GPVI-Fc*Fab2. The very rapid binding of cross-linked
GPVI-Fc to collagen delayed and reduced the forma-
tion of collagen-induced platelet aggregate formation
at 2 and 5 min after start of ﬂow (Figures 3B and 3C).
As in the static assays, bare Fc protein cross-
linked with anti–human-Fc IgG or anti–human-FcFab2 did not inhibit plaque- and collagen-stimulated
platelet aggregation under ﬂow (Supplemental
Figure 1). We found that the ratio of GPVI-Fc to
antibody was crucial for platelet inhibition. A 1:1
ratio of GPVI-Fc:anti–human-Fc Fab2 (presumably
generating longer linear complexes) was more
effective in inhibiting plaque-induced platelet ag-
gregation in ﬂowing blood than a ratio of 1:0.5
(Supplemental Figure 2). GPVI-Fc*Fab2-XL seemed
to inhibit plaque-stimulated platelet aggregation
under ﬂow even better than anti-GPVI antibodies
(Supplemental Figure 3).
The protein complexes formed by the interaction
of GPVI-Fc with anti–human-Fc IgG or anti–human-Fc
Fab2 antibodies were characterized by analytical
FIGURE 3 Cross-Linking of GPVI-Fc With Anti–Human-Fc IgG or Anti–Human-Fc Fab2 Increases Its Inhibition of Platelet Aggregation Stimulated by
Collagen or Plaque Under Flow
Buffer (control), GPVI-Fc, or GPVI-Fc (50 mg/ml; 333 nM) premixed with equimolar anti–human-Fc IgG or anti–human-Fc Fab2 antibodies for crosslinking was added to
blood containing DiOC6 for platelet visualization and perfused over plaque homogenate at a shear rate of 600/s. (A) Representative micrographs display platelet
coverage of plaque at 2, 5, and 9 min after start of blood ﬂow. (B) Effect of buffer, GPVI-Fc, GPVI-Fc*IgG-XL, or GPVI-Fc*Fab2-XL on the kinetics of platelet deposition
from ﬂowing blood onto plaque and collagen. Measurements are each second. Mean (solid line)  SD (shaded area); n ¼ 4 to 6. Comparison at 2, 5, and 9 min by using
repeated measures analysis of variance or if inappropriate by repeated measures analysis of variance on ranks (only 2 min). Signiﬁcance of secondary pair-wise com-
parisons by Tukey correction is indicated by bars. *p < 0.05. (C) Kinetics of not cross-linked and cross-linked GPVI-Fc binding to collagen. (Videos 3 and 4 present
additional details.) GPVI-Fc pre-incubated with PE-labeled anti–human-Fc Fab2 (20:1 mol/mol) (GPVI-Fc*Fab2) or with an equimolar mixture of PE-labeled and unla-
beled anti–human-Fc Fab2 (1:10) for cross-linking (GPVI-Fc*Fab2-XL), was added to blood (333 nM GPVI-Fc ﬁnal concentration) containing abciximab and perfused over
collagen at a shear rate of 600/s. Binding of PE-labeled GPVI-Fc (cross-linked or not cross-linked) to collagen was quantiﬁed every second by ﬂuorescence microscopy
using a 10 objective. Top: Time course of GPVI-Fc*Fab2 and GPVI-Fc*Fab2-XL binding to collagen (area coverage). Mean (solid line)  SD (shaded area); n ¼ 4.
Bottom: Fluorescence intensity surface plots of GPVI-Fc*Fab2 and GPVI-Fc*Fab2-XL bound to collagen at 3 min after start of blood ﬂow. Color gradients indicate
increase of ﬂuorescence intensity. Abbreviations as in Figures 1 and 2.
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136ultracentrifugation (Supplemental Figure 4). This
method provides hydrodynamic and thermodynamic
information concerning the size, shape, and in-
teractions of macromolecules. For not cross-linked
and cross-linked complexes of GPVI-Fc with anti–
human-Fc IgG, we found 3 peaks with similar
Svedberg values but a different distribution of the
protein’s abundance. When anti–human-Fc Fab2 wasused, a shift to higher Svedberg values was found,
indicating the formation of protein complexes of
higher molecular weight and possibly different con-
ﬁgurations of Fab2 cross-linked complexes. Tentative
structures of GPVI-Fc*IgG-XL and GPVI-Fc*Fab2-XL
complexes based on the approximate molecular
weight of the main peaks (approximately 400 to 800
kDa) are depicted in Supplemental Figure 4B. They
FIGURE 4 SIM Imaging of Binding of GPVI-Fc (Not Cross-Linked and Cross-Linked) and Platelets to Collagen
GPVI-Fc was incubated with anti–human-Fc antibodies in a 20:1 molar ratio (GPVI-Fc*IgG, GPVI-Fc*Fab2) or in a 1:1 molar ratio for crosslinking (GPVI-Fc*IgG-XL,
GPVI-Fc*Fab2-XL). The antibodies contained 10% PE-conjugated anti–human-Fc IgG or anti–human-Fc Fab2. The mixtures were added to blood (333 nM GPVI-Fc)
containing abciximab before perfusion over collagen at a shear rate of 600/s. After 4 min of ﬂow, platelets were ﬁxed and stained with anti-CD41 antibody and DyLight
488-conjugated secondary Ab. (Left) Structured illumination microscopy (SIM) images showing binding of PE-labeled GPVI-Fc (not cross-linked and cross-linked) (red)
and platelets (green) to collagen with enlarged sections (800) on the right. Maximum intensity projections of 0.15 mm z sections (total z 2.5 mm) are shown. (Right)
Line intensity proﬁles (maximum intensity 100%) drawn along comparable, platelet-free segments of collagen ﬁbers in the designated images (left). Images are
representative of 5 different experiments. Binding of not cross-linked GPVI-Fc to collagen is discontinuous, showing ﬁber segments that are not occupied by GPVI-Fc
(zero intensity in line proﬁles). Abbreviations as in Figures 1 and 2.
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137show the predominant formation of oligomeric
([GPVI-Fc]2 and [GPVI-Fc]3) complexes.
The accretion of ﬂuorescent-labeled GPVI-Fc and
cross-linked GPVI-Fc from ﬂowing blood onto collagen
ﬁbers and the relation to platelet adhesionwas studied
by using nanoscopy. Conditions and GPVI-Fc/antibody
ratios were similar to that shown in Supplemental
Figure 4, in which the samples had been character-
ized by analytical ultracentrifugation. Imaging using
structured illumination microscopy (SIM) of samples
ﬁxed after blood perfusion showed that not cross-
linked GPVI-Fc*IgG and GPVI-Fc*Fab2 was bound tocollagen in a dotty and inhomogeneous manner,
leaving segments on collagen free which, in fact,
platelets used for surface membrane anchoring
(Figure 4). In contrast, GPVI-Fc*IgG-XL and GPVI-
Fc*Fab2-XL binding to collagen was abundant,
continuous, and rapid enough to virtually prevent
platelet attachment. The qualitative observations
were conﬁrmed by quantitative measurements.
The superior potency of GPVI-Fc*IgG-XL and
GPVI-Fc*Fab2-XL to prevent platelet adhesion to
collagen ﬁbers compared with GPVI-Fc was clearly
visible by SIM (Figure 5). Stable platelet adhesion
FIGURE 5 SIM and STED Imaging of Collagen Stained With Not Cross-Linked GPVI-Fc (GPVI-Fc*IgG, GPVI-Fc*Fab2) and Cross-Linked GPVI-Fc
(GPVI-Fc*IgG-XL, GPVI-Fc*Fab2-XL)
GPVI-Fc was incubated with Alexa Fluor 488-conjugated anti–human-Fc IgG or anti–human-Fc Fab2 antibodies in either a 10:1 molar ratio (not cross-linked GPVI-Fc) or a
1:1 molar ratio (cross-linked GPVI-Fc). The mixtures were then incubated with collagen coated glass coverslips. (A) SIM imaging. The SIM micrographs are maximum
intensity projections of 0.15 mm z sections (total z 1.5 mm). The image is representative of 5 others from different experiments. (B) Stimulated emission depletion (STED)
microscopy imaging. Collagen coated glass coverslips were stained simultaneously with AlexaFluor594-labeled anti-collagen type I and type III antibodies (red) in
addition to GPVI-Fc, which was either labeled or cross-linked with anti–human-Fc antibodies. Yellow indicates co-localization of cross-linked GPVI-Fc with anti-collagen
antibodies. Abbreviations as in Figures 1, 2, and 4.
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138measured in the same samples was drastically reduced
by cross-linking of GPVI-Fc (–76%) with anti–human-
Fc Fab2.
Optical nanoscopy using SIM and STED microscopy
(for even higher resolution) of collagen ﬁbers incu-
bated with ﬂuorescent-labeled GPVI-Fc and GPVI-Fc
cross-linked with anti–human-Fc IgG or anti–human-
Fc Fab2 revealed a continuous and homogeneous
binding compared with the dotted pattern of not
cross-linked GPVI-Fc (Figures 5A and 5B). In the STED
micrographs, in which collagen was simultaneously
stained with AlexaFluor594-conjugated anti-collagen
type I and III antibodies, binding of cross-linkedGPVI-Fc to collagen showed complete co-localization
with the anti-collagen antibodies.
To conﬁrm our hypothesis that it is in fact
cross-linking that potentiates the inhibitory effect
of GPVI-Fc, inhibition of platelet aggregation on
plaque and collagen ﬁbers by GPVI-Fc*Fab2-XL were
compared with that by GPVI-Fc*Fab. Fab antibodies
bear only 1 antigen-binding site and are unable to
cross-link antigens. Plaque- or collagen-coated sur-
faces were pre-incubated with either GPVI-Fc*Fab or
GPVI-Fc*Fab2-XL. As expected, virtually no effect of
GPVI-Fc*Fab was observed in contrast to a complete
inhibition of plaque- and collagen-induced platelet
FIGURE 6 GPVI-Fc*Fab in Contrast to GPVI-Fc*Fab2-XL Does Not Inhibit Platelet Aggregation Induced by Plaque and Collagen Under Flow: Functional and SIM
Imaging Studies
GPVI-Fc (100 mg/ml; 666 nM) was incubated with 3-fold molar excess of anti–human-Fc Fab-AlexaFluor594 (GPVI-Fc*Fab) or equimolar concentrations of
anti–human-Fc Fab2 or anti-human-Fc Fab2–PE (GPVI-Fc*Fab2-XL). (A) Effect of GPVI-Fc*Fab and GPVI-Fc*Fab2-XL on the kinetic of platelet deposition onto
plaque and collagen in ﬂowing blood. Plaque homogenate and collagen coated onto coverslips were incubated with GPVI-Fc*Fab and GPVI-Fc*Fab2-XL complexes
before perfusion with blood at a shear rate of 600/s. Fluorescence images of platelet deposition were continuously recorded (1 frame/5 s) and analyzed as detailed
in the Methods section. Mean  SD; n ¼ 4. Comparison by using analysis of variance for repeated measures at full 2 to 5 min and secondary pair-wise comparisons
by using Tukey correction. Signiﬁcance of pair-wise comparison of GPVI-Fc*Fab2-XL to control and to GPVI-Fc*Fab was equal at all time points and is only
indicated by a single line with asterisks. *p < 0.05; **p < 0.01; ***p < 0.001. (B) SIM imaging of GPVI-Fc*Fab and GPVI-Fc*Fab2-XL binding and platelet
adhesion to collagen ﬁbers. Collagen-coated coverslips were incubated with GPVI-Fc*Fab-AlexaFluor594 or GPVI-Fc*Fab2-PE-XL (red) before perfusion with blood
containing abciximab at a shear rate of 600/s. After 4 min of ﬂow, platelets were ﬁxed and stained with anti-CD41 antibody and DyLight 488-conjugated second
Ab (green). (Left) SIM micrographs (maximum intensity projections of 0.15 mm z sections (total z 2.5 mm) with enlarged sections (800) showing the different
pattern of GPVI-Fc*Fab and GPVI-Fc*Fab2-XL binding (red) to collagen. Platelet adhesion (green) to collagen is observed in GPVI-Fc*Fab but not GPVI-Fc*Fab2-XL
treated samples (left). Images are representative of 5 different experiments. (Right) Line intensity proﬁles (maximum intensity 100%) along comparable, platelet-
free sections of collagen ﬁbers in the designated images (left). Binding of GPVI-Fc*Fab to collagen is discontinuous with segments of ﬁbers lacking signiﬁcant
binding (<10% in line proﬁles). Abbreviations as in Figures 1, 2, and 4.
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139aggregation by GPVI-Fc*Fab2-XL, indicating that
indeed cross-linking causes the potent inhibition
by GPVI-Fc*Fab2-XL (Figure 6A). Analysis by using
SIM imaging demonstrated the absence of platelet
adhesion to collagen ﬁbers in the GPVI-Fc*Fab2-XL
samples and a reticulated, dense binding pattern of
GPVI-Fc*Fab2-XL binding in contrast to the staggered
pattern of GPVI-Fc*Fab binding; this approach left
ﬁber segments free for platelet membrane contacts.The qualitative observations were conﬁrmed by
quantitative measurements (Figure 6B).
To test whether cross-linked GPVI-Fc would in-
crease bleeding time, measurements were conducted
by using the platelet function analyzer PFA-200
(Siemens Healthcare, Germany). This device simu-
lates primary hemostasis in vitro and is used
for routine screening of patients with potential hem-
orrhagic risk (23,24). GPVI-Fc*Fab2-XL did not
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140signiﬁcantly increase the closure times measured with
the PFA-200 collagen/adenosine diphosphate or
collagen/epinephrine cartridges compared with buffer
or GPVI-Fc (Figure 7). As expected, aspirin produced a
prolonged closure time with the collagen/epinephrine
cartridge.
DISCUSSION
We found that cross-linking of GPVI-Fc with Fc-
directed antibodies drastically increased its potency
to inhibit atherosclerotic plaque- and collagen-
induced platelet aggregation under static and ﬂow
conditions. The increase in efﬁcacy was obviously
due to cross-linking per se and not to saturation of
other Fc-binding sites with anti–human-Fc anti-
bodies. First, analytical ultracentrifugation conﬁrmed
the formation of cross-linked GPVI-Fc complexes af-
ter incubating GPVI-Fc with equimolar amounts of
anti–human-Fc IgG or Fab2 antibodies. Second,
functional platelet experiments under ﬂow and
nanoscopic imaging studies comparing the effect of
GPVI-Fc incubated with anti–human-Fc Fab2 or Fab0
antibodies (which cannot cross-link) unequivocally
showed that cross-linking of the Fc domains of
GPVI-Fc is the underlying mechanism.
In blood, the addition of GPVI-Fc cross-linked
with anti–human-Fc Fab2 led to an even stronger
inhibition of plaque- and collagen-induced platelet
aggregation than the addition of GPVI-Fc cross-linked
with anti–human-Fc IgG, particularly under ﬂow con-
ditions (Figure 3). A possible explanation for the
stronger inhibition with Fab2-containing complexes
could be that GPVI-Fc*Fab2-XL complexes cannot
again be stripped from plaque collagen by blood cellsFIGURE 7 GPVI-Fc*Fab2-XL Does Not Increase In Vitro Bleeding
Blood was either pre-incubated with no supplement, buffer, aspirin (ASA)
transfer to collagen/adenosine diphosphate (ADP) or collagen/epinephri
platelet function analyzer PFA-200. Mean  SD; n ¼ 6. ***p < 0.001 b
comparison of ASA versus all other conditions. Abbreviations as in Figurcarrying the Fc receptor what might happen to GPVI-
Fc*IgG-XL complexes. Particularly after rapid bind-
ing of cross-linked GPVI-Fc*IgG-XL to plaque collagen
in the ﬂow studies, the goat Fc tails might be well
accessible for the Fc receptors of nearby ﬂowing blood
cells. This might explain the different kinetics and
degree of inhibition by anti-Fc Fab2- and IgG cross-
linking of GPVI-Fc in the ﬂow studies (Figure 3B).
Advanced microscopic imaging studies provided
insights into the mechanism of improved platelet in-
hibition by GPVI-Fc cross-linking. Notably, collagen
ﬁbers bound labeled GPVI-Fc from ﬂowing blood
very rapidly and stably; there was only a small differ-
ence in the binding kinetics between cross-linked and
not cross-linked GPVI-Fc but a higher plateau level of
cross-linked GPVI-Fc binding. Nanoscopy using
SIM and STED microscopy showed that GPVI-Fc cross-
linkedwith anti–human-Fc IgG or anti–human-Fc Fab2
bound to collagen in a more continuous and homoge-
neous manner compared with the dotted binding
pattern of not cross-linked GPVI-Fc. Cross-linked
GPVI-Fc covered collagen similar to a sheath,
thereby impeding platelets to contact binding motifs
on collagen. Cross-linking obviously generates mul-
tiple linear oligomeric GPVI-Fc complexes providing
high-density alignment of GPVI domains with their
corresponding collagen-binding motifs (Figure 8).
The increase in efﬁcacy by GPVI-Fc cross-linking
could lead to several advantages for future anti-
platelet treatments of cardiovascular patients. First,
cross-linked GPVI-Fc offers effective platelet inhibi-
tion on sites of plaque rupture independent of
the actual ﬂow rate. Second, the inhibitory effect of
cross-linked GPVI-Fc on plaque-induced platelet ag-
gregation is at least as potent as that of anti-GPVI(300 mg/ml), GPVI-Fc (333 nM), or GPVI-Fc*Fab2-XL (333 nM) before
ne cartridges and determination of the in vitro closure time with the
y repeated measures analysis of variance and secondary pair-wise
e 2.
FIGURE 8 Model of GPVI-Fc and Cross-Linked GPVI-Fc Binding to Plaque Collagen
Cross-linking of dimeric glycoprotein VI–fragment crystallizable (GPVI-Fc) fusion protein
(GPVI, brown; Fc, blue) by anti–Fc Fab2 creates oligomeric (n ¼ 2 to 4) GPVI-Fc molecules,
which bind to their corresponding motifs on collagen ﬁbers more densely (bottom) than
GPVI-Fc (top).
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141antibodies, but it is focused on the injured lesion and
not burdened with systemic antiplatelet effects (un-
like that of anti-GPVI antibodies). In fact, anti-GPVI
antibodies may increase bleeding. Although the tail
bleeding time of GPVI-deﬁcient mice is only moder-
ately increased (14), a variable bleeding diathesis is
observed in patients with rare genetic or acquired
GPVI defects (25).
Finally, due to the high efﬁcacy, cross-linked GPVI-
Fc can be used in much lower doses than GPVI-Fc.
Moreover, under arterial ﬂow inhibition by cross-
linked GPVI-Fc, complexes appeared to be even
more pronounced if stimulated by human plaque
material than by collagen ﬁbers alone (Figure 3). This
further focuses its action to the injured plaque and
may translate to a reduced risk of systemic bleeding.
Indeed, by measuring closure time with the PFA-200
device, we found no evidence that cross-linked
GPVI-Fc increases bleeding time in vitro.
When atherothrombosis causes acute myocardial
infarction or ischemic stroke, a highly efﬁcient anti-
platelet therapy is needed. We demonstrated that the
new principle of generating multimeric GPVI com-
plexes (e.g., by antibody cross-linking of GPVI-Fc)
exploits the full local potential of GPVI antagonism
in human plaque–induced platelet adhesion and ag-
gregation while leaving systemic platelet function
intact. Cross-linked GPVI-Fc complexes in the
bloodstream very rapidly accrete onto denuded pla-
que collagen ﬁbers and cover them continuously and
stably. This approach efﬁciently prevents platelet
arrest and aggregate formation. The rapid deploy-
ment to the triggering plaque lesion, its high local
potency, and the lack of systemic platelet impairment
combine to make an attractive pharmacodynamic
proﬁle that should inspire the development of new
poly-GPVI domain–based drugs targeting plaque
collagen–platelet interaction. We envision that GPVI
oligomers could be further tailored for clinical appli-
cation. Antibody cross-linked GPVI-Fc complexes
with persistent coating of collagen exposed at the
lesion but limited stability in the circulation due to
dissociation of the antibody from GPVI-Fc may be
preferable; an example is for percutaneous coronary
interventions in which a short-term, but highly
effective, lesion-focused antithrombotic action is
desired at the moment of dilation of a stenosing pla-
que. In fact, human monoclonal antibodies against Fc
selected from a human combinatorial antibody library
are already available and could, in principal, be
further developed for GPVI-Fc complexing in clinical
studies. Other strategies might be preferred,
including transforming GPVI domains by chemical
linking into a multivalent format with long-termstability in the circulation and avoiding potential
immunogenic problems of GPVI-Fc antibody com-
plexes. These approaches might be used if a pro-
longed protection from thrombogenic de novo plaque
collagen exposure is desired, such as in patients with
recurrent embolism from plaque erosion (26).
CONCLUSIONS
Cross-linking GPVI-Fc into oligomeric complexes
aligned GPVI domains densely with their corre-
sponding binding motifs on collagen and strikingly
enhanced GPVI-Fc suppression of platelet adhesion
and plaque- and collagen-induced aggregation under
static and ﬂow conditions without increasing
bleeding time in vitro. Transformation of GPVI into
multivalent GPVI complexes may provide a new
strategy for a highly effective and safe GPVI targeting
treatment against acute atherothrombosis.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: GPVI
mediates platelet activation by injured plaques exposing
collagen. This scenario can be blocked by GPVI antibodies
possibly burdened with systemic platelet dysfunction or,
less potently, by a GPVI-Fc fusion protein that conceals
GPVI-binding motifs on collagen of lesioned plaques from
platelets but leaves systemic platelet function intact.
We demonstrate here that cross-linking the Fc tails of
GPVI-Fc to form oligomeric GPVI-Fc complexes results
in a rapid continuous coverage of collagen ﬁbers and
complete prevention of platelet aggregation on human
plaque in static and ﬂow models without increasing
bleeding time. Thus, the full potential of blocking the
collagen–GPVI axis of platelet activation can be provided
at the culprit lesion by linking GPVI-Fc to oligomeric
complexes while systemic platelet function is preserved.
TRANSLATIONAL OUTLOOK: Cross-linked GPVI-Fc,
which rapidly binds to the site of plaque injury, might
prevent atherothrombosis with no increased risk of
systemic bleeding. This approach may hold special
promise in intervention-associated plaque trauma, in
which suppression of initiating platelet activation is
desired to attenuate ensuing steps to restenosis.
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